Development of enterovirus 71 vaccines
Journal
Expert Review of Vaccines
Journal Volume
9
Journal Issue
2
Pages
149-156
Date Issued
2010
Author(s)
Lee M.-S.
Abstract
Enterovirus 71 (EV71) was first isolated in 1969 in California, USA. Several epidemic outbreaks with high mortality rates have occurred in European and Asian Countries (Bulgaria in 1975, Hungary in 1978, Malaysia in 1997, Taiwan in 1998 and China in 2008). EV71 CNS involvement may be associated with neurological sequelae, delayed neurodevelopment and reduced cognitive functioning. Since poliovirus was nearly eradicated by vaccination, EV71 is now considered as one of the top candidates for new vaccine development against human enteroviruses. Recently, several EV71 vaccine candidates, including live-attenuated virus, inactivated whole virus, recombinant viral protein, virus-like particle and DNA vaccines, have been evaluated in animals but no clinical trial has yet been conducted. Based on historical experiences with poliovirus vaccines and animal studies, the inactivated whole-virus vaccines are feasible and could be licensed readily, so these are targeted for preparing clinical trials in several organizations in Asia. ? 2010 Expert Reviews Ltd.
Subjects
Enterovirus 71; Epidemiology; Genotype; Sequelae; Vaccine
SDGs
Other Subjects
DNA vaccine; inactivated vaccine; live vaccine; vaccine; virus protein; virus vaccine; Bulgaria; central nervous system disease; China; cognition; Enterovirus 71; Enterovirus infection; human; Hungary; Malaysia; mortality; nerve cell differentiation; nonhuman; priority journal; review; risk factor; Taiwan; vaccine production; virus like agent; virus transmission; animal; clinical trial; Enterovirus; immunology; Animals; Clinical Trials as Topic; Enterovirus A, Human; Enterovirus Infections; Humans; Vaccines, Inactivated; Viral Vaccines
Type
review